Increased serum cholesterol and long-chain fatty acid levels are associated with the efficacy of nivolumab in patients with non-small cell lung cancer.
Karayama M, Inui N, Inoue Y, Yoshimura K, Mori K, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Asada K, Uto T, Fujii M, Matsui T, Matsuura S, Hashimoto D, Toyoshima M, Kusagaya H, Matsuda H, Inami N, Kaida Y, Niwa M, Ito Y, Suda T.
Karayama M, et al. Among authors: hashimoto d.
Cancer Immunol Immunother. 2022 Jan;71(1):203-217. doi: 10.1007/s00262-021-02979-4. Epub 2021 Jun 5.
Cancer Immunol Immunother. 2022.
PMID: 34091744
Free PMC article.